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To evaluate the diagnostic value and the complication rate of US-FNA of pancreatic focal masses by reporting ten-year experiences from two high-volume centers for pancreatic pathology.
All clinical, radiologic and pathologic data of patients who underwent percutaneous US-FNA of pancreatic masses were retrospectively evaluated. Inclusion periods were January 2004-September 2014 for Center 1 and January 2002-December 2012 for Center 2. The following data were analyzed: size and location of the lesion; number of needle passages; number of smeared slides; cytological report; final histologic diagnosis after surgical resection or clinical-radiologic follow-up findings; onset of complications (# 7 days after the procedure or until discharge when discharge occurred before day 7). Indications for US-FNA were: a non-resectable (metastatic or locally-advanced) pancreatic lesion before neo-adjuvant therapies; inconclusive or controversial aspects at previous imaging; suspect of an uncommon neoplasm that could influence the prognosis (for example, metastases) or that could be better managed other than surgically (for example, lymphoma). Each lesion had been evaluated with CT, MR or contrast-enhanced US before FNA. Prior to the sample all patients were asked to sign an informed consent.
All US-FNAs were performed in Center 1 with a Sequoia 512 US equipment (Acuson, Mountain View, CA, USA), using a convex probe with a lateral guidance kit ( Fig. 1 on  page 4 ) and 20 or 21 G modified Menghini-type needles ( Fig. 2 on page 4 ) . The samples were immediately smeared on a glass slide, fixed with 95% alcohol and stained with modified Papanicolau method. An experienced cytopathologist attended the whole procedure and immediately evaluate the sample, providing an assessment of adequacy and the immediate diagnosis. In Center 2, US-FNAs were performed by a single radiologist using an Aplio XG US equipment (Toshiba Medical Systems, Japan) and 20G Chiba needles; the same radiologist smeared and fixed the sample on glass slides. Samples were then stained and evaluated by an expert pathologist who did not attended the procedure.
Samples were considered diagnostic when a pathology report was made. FNA was considered true positive if the result was positive or strongly suggestive of malignancy ("atypia" or "suspicious for malignancy"). FNA was considered true negative if the result was negative for malignancy, without subsequent clinical or imaging follow-up findings suggestive of malignancy. FNA sample was considered false negative if the result was negative for malignancy but clinical or imaging follow-up findings suggested malignancy. FNA was considered false positive if the result was positive but clinical setting or imaging findings suggested the benignity of the lesion. 
Results
A total of 2024 patients (1106 men; 918 women) were included in this study, 57,8% from Center 1 and 42,2% from Center 2. Mean lesion size was 42 mm (range 10-150 mm); lesions were mainly located ( Fig. 3 on page 8 ) in the right pancreas (64,9%). The mean number of needle passes was one (range, 1-4). A mean of 8 slides per patient were prepared (range, 1-23).
Sampling was diagnostic in 92,2% procedures (1867/2024); Center 1 had a higher rate of diagnostic samples (95,9%) as compared to Center 2 (87,2%). Patients with nondiagnostic samples had a final diagnosis after further examinations in 102/157 cases (65%), while 55 patients were lost at follow-up. There were 100 negative samples. There were no false-positive FNA results. Considering the 157 non-diagnostic samplings as false-negatives, percutaneous US-FNA had overall sensitivity and accuracy of 90,7% and 91%, respectively. Excluding non-diagnostic samples, percutaneous US-FNA had 98,7% sensitivity, 100% specificity and positive predictive value, 75,5% negative predictive value, and 98,7% accuracy.predictive values, and accuracy. All non-diagnostic samples (N=157) were excluded from this evaluation.
In 2007 of the 2024 cases (99,2%), the procedure was uneventful, so short-term complication rate was 0,8%. No major complications occurred. In 5 patients, abdominal fluid was found immediately after the procedure: follow-up evaluation showed no adverse consequences. 12 patients experienced post-procedural pain without clinically significant findings at subsequent imaging. 
Conclusion
In our experience, ultrasound-guided percutaneous fine-needle aspiration is a sensitive, safe, and accurate procedure for the diagnosis and planning of therapy for focal pancreatic lesions. Benign FNA findings cannot be used to exclude a pancreatic malignancy, and repetition of the sample or strict follow-up should be considered if there is high clinical or radiologic suspicion of a malignancy. The onsite presence of a cytologist and the use of aspiration needles lead to a high rate of acquisition of diagnostic-quality samples, reducing the need for patient recall. 
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